Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym

Article Stock Quotes (1) Comments (0)

Several analyst firms have revised price targets and estimates on shares of Corcept Therapeutics (Nasdaq: CORT) following news of FDA approval for its Korlym. Corcept shares last traded at $4.42, up more than 46 percent from Friday's closing price.

• JMP Securities - from $9 to $11, Market Outperform maintained
  
• Stifel Nicolaus - from $7 to $9, Buy maintained
  
• Ladenburg Thalmann - from $6 to $7, Buy maintained

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Corcept.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• NetApp (NTAP) Post Solid Q4, Numbers Bumped - Needham & Company
• UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel Nicolaus, JMP Securities, Ladenburg Thalmann Financial Services

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?